1.
Georg Aue, Margaret A. Lindorfer, Paul V. Beum, Andrew W. Pawluczkowycz, Berengere Vire, Thomas Hughes, Ronald P. Taylor, Adrian Wiestner. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. haematol [Internet]. 2010Feb.5 [cited 2024May18];95(2):329-32. Available from: https://haematologica.org/article/view/5506